MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 78
- Registration Number
- NCT01806298
- Locations
- 🇬🇧
Research site, Truro, United Kingdom
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 93
- Registration Number
- NCT01791244
- Locations
- 🇸🇪
Research Site, Örnsköldsvik, Sweden
🇩🇪Please contact the Merck Communications Service for Recruiting locations, Darmstadt, Germany
🇸🇪Research site, Ängelholm, Sweden
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 90
- Registration Number
- NCT01746862
- Locations
- 🇰🇷
Please contact Merck KGaA Communication Center for Recruiting Sites, Located in, Korea, Republic of
A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 67
- Registration Number
- NCT01735422
- Locations
- 🇨🇦
Royal University Hospital, Saskatoon, Saskatchewan, Canada
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT01731587
Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 90
- Registration Number
- NCT01732471
- Locations
- 🇩🇪
Please contact Merck KGaA Communication Center, Darmstadt, Germany
Oral Bioavailability and Mass Balance Trial With Pimasertib
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT01713036
- Locations
- 🇭🇺
Research Site, Budapest, Hungary
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 26
- Registration Number
- NCT01668017
- Locations
- 🇯🇵
Please contact, Merck Serono Co., Ltd for recruiting locations in, Japan
Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 81
- Registration Number
- NCT01653743
- Locations
- 🇯🇵
Bashamichi Ladies Clinic, Kanagawa, Japan
🇯🇵Hanabusa Women's Central Fertility Clinic, Hyogo, Japan
🇯🇵Sophia Ladies Clinic, Kanagawa, Japan
An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device
Completed
- Conditions
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 230
- Registration Number
- NCT01601080
- Locations
- 🇬🇧
Please contact the, Merck KGaA Communication Center for recruiting locations, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath